Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients

Launched by PEKING UNIVERSITY THIRD HOSPITAL · Nov 30, 2022

Keywords

ClinConnect Summary

This clinical trial is studying whether a medication called conbercept, used after a specific eye surgery known as vitrectomy, can help reduce complications in patients with a condition called Proliferative Diabetic Retinopathy (PDR). PDR is a serious eye problem that can occur in people with diabetes. The trial is looking for participants who are undergoing vitrectomy for PDR, and it is currently recruiting patients aged between 18 and 75 years old, regardless of gender.

To be eligible for this study, participants must not have received certain treatments, like anti-VEGF injections or steroids, in the months leading up to their surgery. If you join the study, you can expect to receive close monitoring and care from the medical team as they gather information on how well conbercept works in preventing complications after surgery. This trial is important because it aims to find better ways to help patients recover from surgery and improve their eye health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • PDR patients undergoing vitrectomy
• Exclusion Criteria:
• • patients who had received intravitreal injection or systemic use of all types of anti-VEGF agents in the recent three months before vitrectomy
• • patients who had received intravitreal injection or systemic use of all types of steroid in the recent one month before vitrectomy
• • patients who had received complete PRP before vitrectomy
• • patients who are pregnant

Trial Officials